CADL vs. AVXL, TRML, STRO, MGTX, AURA, JSPR, REPL, CCCC, TNYA, and URGN
Should you be buying Candel Therapeutics stock or one of its competitors? The main competitors of Candel Therapeutics include Anavex Life Sciences (AVXL), Tourmaline Bio (TRML), Sutro Biopharma (STRO), MeiraGTx (MGTX), Aura Biosciences (AURA), Jasper Therapeutics (JSPR), Replimune Group (REPL), C4 Therapeutics (CCCC), Tenaya Therapeutics (TNYA), and UroGen Pharma (URGN). These companies are all part of the "medical" sector.
Candel Therapeutics (NASDAQ:CADL) and Anavex Life Sciences (NASDAQ:AVXL) are both small-cap medical companies, but which is the better business? We will compare the two companies based on the strength of their valuation, risk, earnings, dividends, institutional ownership, media sentiment, profitability, community ranking and analyst recommendations.
Candel Therapeutics has a beta of -0.94, indicating that its share price is 194% less volatile than the S&P 500. Comparatively, Anavex Life Sciences has a beta of 0.66, indicating that its share price is 34% less volatile than the S&P 500.
13.9% of Candel Therapeutics shares are held by institutional investors. Comparatively, 31.6% of Anavex Life Sciences shares are held by institutional investors. 44.6% of Candel Therapeutics shares are held by insiders. Comparatively, 11.0% of Anavex Life Sciences shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.
Candel Therapeutics has higher revenue and earnings than Anavex Life Sciences. Anavex Life Sciences is trading at a lower price-to-earnings ratio than Candel Therapeutics, indicating that it is currently the more affordable of the two stocks.
In the previous week, Candel Therapeutics had 3 more articles in the media than Anavex Life Sciences. MarketBeat recorded 7 mentions for Candel Therapeutics and 4 mentions for Anavex Life Sciences. Anavex Life Sciences' average media sentiment score of 1.04 beat Candel Therapeutics' score of 0.22 indicating that Anavex Life Sciences is being referred to more favorably in the news media.
Anavex Life Sciences received 416 more outperform votes than Candel Therapeutics when rated by MarketBeat users. Likewise, 74.13% of users gave Anavex Life Sciences an outperform vote while only 50.00% of users gave Candel Therapeutics an outperform vote.
Anavex Life Sciences' return on equity of -29.04% beat Candel Therapeutics' return on equity.
Candel Therapeutics currently has a consensus target price of $11.00, indicating a potential upside of 28.65%. Anavex Life Sciences has a consensus target price of $40.00, indicating a potential upside of 882.80%. Given Anavex Life Sciences' higher probable upside, analysts clearly believe Anavex Life Sciences is more favorable than Candel Therapeutics.
Summary
Anavex Life Sciences beats Candel Therapeutics on 9 of the 14 factors compared between the two stocks.
Get Candel Therapeutics News Delivered to You Automatically
Sign up to receive the latest news and ratings for CADL and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding CADL and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Candel Therapeutics Competitors List
Related Companies and Tools
